FDA Warning Letters · October 20, 2026 · Primary source
Signature Formulations LLC
Summary
FDA's Center for Drug Evaluation and Research issued a warning letter dated October 1, 2026, to Signature Formulations LLC of Phoenix, Arizona, citing systemic CGMP violations including cross-contamination of drug products manufactured on shared equipment. Laboratory analysis of distributed lots confirmed contamination with undeclared active ingredients across all sampled lots, and FDA classified the affected products as adulterated under sections 501(a)(2)(A) and 501(a)(2)(B) of the FD&C Act. FDA recommended a voluntary recall of all affected products, which the firm verbally committed to execute, and also noted a prior 2025 recall and a prior warning letter from January 2026 for the same facility.
What this may mean
Signature Formulations has committed to halt manufacturing and distribution and to voluntarily recall all affected drug products currently in U.S. distribution. FDA warned that failure to remediate violations may result in seizure, injunction, withholding of export certificates, and delays in approval of new applications listing the firm as a manufacturer. The facility's repeated CGMP failures, including a second warning letter within less than a year, place it at elevated risk of import alert or consent decree.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- FDA Warning Letters · October 14, 2026SCA Pharmaceuticals, LLCScore 50
- FDA Warning Letters · October 7, 2026Amazon.com, Inc.Score 46
- FDA Warning Letters · October 20, 2026Rohto Pharmaceutical Co., Ltd.Score 43
- FDA Warning Letters · October 6, 2026Online Generic Medicine/www.onlinegenericmedicine.comScore 43
- FDA Warning Letters · October 20, 2026Olympus Medical Systems CorporationScore 40
- FDA Warning Letters · October 20, 2026Baxter International Inc.Score 38